Product image of Montelair Hexal (Montelukast) supplied by GNH India

Montelair Hexal

Active Ingredient:
Montelukast
Origin:
EU

Montelair Hexal (Montelukast)

Montelukast, the active ingredient in Montelair Hexal, is a leukotriene receptor antagonist presented as tablets for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in both adults and children who require long‑term control of airway inflammation. This therapy also helps reduce symptoms and improve quality of life.

GNH India supplies Montelair Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast is a leukotriene receptor antagonist used to treat conditions mediated by cysteinyl leukotrienes.

  • Asthma: Improves control of chronic asthma by reducing bronchoconstriction and inflammation.
  • Allergic rhinitis: Relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.
  • Exercise‑induced bronchoconstriction: Prevents airway narrowing that occurs during or after physical activity.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells and eosinophils. By antagonising this receptor it prevents leukotriene‑mediated bronchoconstriction, mucus secretion and inflammatory cell recruitment, thereby reducing airway hyper‑responsiveness and the symptoms of asthma and allergic rhinitis. The inhibition is competitive and reversible, allowing normal leukotriene pathways to function when drug levels decline. This targeted action contributes to its favorable safety profile compared with non‑selective anti‑inflammatory agents.

Side Effects

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Headache: mild to moderate headache reported.
  • Abdominal pain: occasional stomach discomfort or cramps.
  • Nausea: feeling of queasiness.
  • Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

  • Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention.
  • Neuropsychiatric events: agitation, depression, or suicidal thoughts, reported rarely.

Precautions & Warnings

When prescribing Montelukast, clinicians should consider several precautionary measures.

  • Indication verification: confirm diagnosis of asthma, allergic rhinitis or exercise‑induced bronchoconstriction before use.
  • Age considerations: safety in children under 12 months has not been established; follow pediatric guidelines.
  • Pregnancy and lactation: use only if potential benefit outweighs risk, as data are limited.
  • Drug interactions: review concomitant medications for potential major interactions.
  • Monitoring: observe for neuropsychiatric symptoms, especially in adolescents.
  • Store at ambient temperature: keep below 25 °C, protect from moisture in original packaging.

Avoid Interactions

Montelukast may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Ritonavir: strong CYP3A4 inhibition can increase montelukast plasma levels, risking toxicity.
  • Phenobarbital: strong CYP3A4 induction may reduce montelukast exposure, decreasing efficacy.

Moderate Interactions (Monitor Closely)

  • Fluconazole: moderate CYP3A4 inhibition may modestly raise montelukast levels.
  • Carbamazepine: enzyme induction may lower montelukast concentrations.
  • Warfarin: occasional reports of altered INR; monitor coagulation parameters.

Frequently Asked Questions

Montelair Hexal contains montelukast, which is indicated for the long‑term management of asthma, relief of symptoms of allergic rhinitis, and prevention of exercise‑induced bronchoconstriction in patients who need control of airway inflammation.

Montelukast blocks the cysteinyl leukotriene receptor CysLT1 on airway cells, preventing leukotrienes from causing bronchoconstriction, mucus production and inflammatory cell recruitment. This reduces airway hyper‑responsiveness and eases symptoms of asthma and allergic rhinitis.

The appropriate dose of Montelair Hexal is determined by the prescribing healthcare professional based on the patient’s age, weight, diagnosis and clinical response. Patients should follow the exact regimen provided by their prescriber.

Safety data for montelukast in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Montelair Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelair Hexal (montelukast) belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It targets leukotriene‑mediated pathways, which can be advantageous for patients who prefer oral therapy or have specific contraindications to inhaled steroids.

Montelair Hexal tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children.

Montelair Hexal is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious but rare adverse events include severe allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric effects like agitation, depression or suicidal thoughts. Patients should seek immediate medical attention if any of these symptoms occur.

Montelair Hexal should be avoided in individuals with known hypersensitivity to montelukast or any component of the tablet. Caution is also advised for patients with uncontrolled severe liver disease, and it is not recommended for children under the age approved for the specific formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT